(Q55060821)

English

Cadralazine did not produce the SLE-syndrome when hydralazine did.

scientific article

In more languages

edit

Statements

instance of

scholarly article

1 reference

stated in

Europe PubMed Central

PubMed publication ID

3556384

retrieved

16 June 2018

reference URL

http://europepmc.org/abstract/MED/3556384

title

Cadralazine did not produce the SLE-syndrome when hydralazine did. (English)

1 reference

stated in

Europe PubMed Central

PubMed publication ID

3556384

retrieved

16 June 2018

reference URL

http://europepmc.org/abstract/MED/3556384

1 reference

O K Andersson

1

1 reference

stated in

Europe PubMed Central

PubMed publication ID

3556384

retrieved

16 June 2018

reference URL

http://europepmc.org/abstract/MED/3556384

publication date

1 January 1987

1 reference

stated in

Europe PubMed Central

PubMed publication ID

3556384

retrieved

16 June 2018

reference URL

http://europepmc.org/abstract/MED/3556384

published in

European Journal of Clinical Pharmacology

1 reference

stated in

Europe PubMed Central

PubMed publication ID

3556384

retrieved

16 June 2018

reference URL

http://europepmc.org/abstract/MED/3556384

volume

31

1 reference

stated in

Europe PubMed Central

PubMed publication ID

3556384

retrieved

16 June 2018

reference URL

http://europepmc.org/abstract/MED/3556384

issue

6

1 reference

stated in

Europe PubMed Central

PubMed publication ID

3556384

retrieved

16 June 2018

reference URL

http://europepmc.org/abstract/MED/3556384

page(s)

741

1 reference

stated in

Europe PubMed Central

PubMed publication ID

3556384

retrieved

16 June 2018

reference URL

http://europepmc.org/abstract/MED/3556384

exact match

https://scigraph.springernature.com/pub.10.1007/bf00541309

0 references

cites work

Controlled clinical trial of cadralazine as a second-step drug in the treatment of hypertension.

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/3556384

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

3-Hydrazinepyridazine derivatives. III. Synthesis and anti-hypertensive activity of new 3-(2-acylhydrazine)-pyridazine-6-alkylamino substitutes

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/3556384

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

DOI

10.1007/BF00541309

1 reference

stated in

Europe PubMed Central

PubMed publication ID

3556384

retrieved

16 June 2018

reference URL

http://europepmc.org/abstract/MED/3556384

Dimensions Publication ID

1034430589

0 references

PubMed publication ID

3556384

1 reference

stated in

Europe PubMed Central

PubMed publication ID

3556384

retrieved

16 June 2018

reference URL

http://europepmc.org/abstract/MED/3556384

(Q55060821)

Cadralazine did not produce the SLE-syndrome when hydralazine did.

Statements

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)